NASDAQ:EYES Second Sight Medical Products Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Second Sight Medical Products, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $2.08 -0.06 (-2.80%) (As of 06/29/2022 12:24 PM ET) Add Compare Share Today's Range$2.06▼$2.1350-Day Range$1.22▼$2.5752-Week Range$1.14▼$5.28Volume1,983 shsAverage Volume456,532 shsMarket Capitalization$81.97 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive EYES Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Second Sight Medical Products and its competitors with MarketBeat's FREE daily newsletter. Email Address EYES Stock Forecast (MarketRank)Overall MarketRank™1.52 out of 5 starsMedical Sector1042nd out of 1,433 stocksElectromedical Equipment Industry21st out of 30 stocksAnalyst Opinion: 0.0Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 - 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Second Sight Medical Products. Previous Next 4.3 Community Rank Outperform VotesSecond Sight Medical Products has received 262 “outperform” votes. (Add your “outperform” vote.)Underperform VotesSecond Sight Medical Products has received 142 “underperform” votes. (Add your “underperform” vote.)Community SentimentSecond Sight Medical Products has received 64.85% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Second Sight Medical Products and other stocks. Vote “Outperform” if you believe EYES will outperform the S&P 500 over the long term. Vote “Underperform” if you believe EYES will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldSecond Sight Medical Products does not currently pay a dividend.Dividend GrowthSecond Sight Medical Products does not have a long track record of dividend growth. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Second Sight Medical Products insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,163,387.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders47.20% of the stock of Second Sight Medical Products is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 9.09% of the stock of Second Sight Medical Products is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Book Value per Share RatioSecond Sight Medical Products has a P/B Ratio of 1.20. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Second Sight Medical Products (NASDAQ:EYES)Second Sight Medical Products, Inc. develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals. It develops technologies to treat the population of sight-impaired individuals. The company offers the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. The company was founded in 1998 and is headquartered in Sylmar, California.Read More EYES Stock News HeadlinesJune 29, 2022 | washingtonpost.comMy miscarriage looked like an abortion. Today, I would be a suspect.June 11, 2022 | americanbankingnews.comSecond Sight Medical Products (NASDAQ:EYES) Stock Passes Above 50-Day Moving Average of $1.72June 5, 2022 | americanbankingnews.comInsider Buying: Second Sight Medical Products, Inc. (NASDAQ:EYES) Director Purchases $174,447.10 in StockApril 14, 2022 | finance.yahoo.comNano Precision Medical Co-Founder and CEO Discusses Proposed Second Sight Merger in Interview to Air on Bloomberg U.S. on the RedChip Money Report®February 17, 2022 | benzinga.comSECOND SIGHT MEDICAL INVESTOR ALERT BY THE FORMER...February 16, 2022 | finance.yahoo.comEYES Stock Pops on Biotech Merger Plans. 5 Things to Know.February 8, 2022 | finance.yahoo.comSecond Sight Medical To Merge With AstraZeneca-Backed Nano Precision MedicalFebruary 8, 2022 | benzinga.comSecond Sight Medical Shares To Resume Trade At 5 p.m. ESTFebruary 8, 2022 | msn.com6 high-tech tools that will take your beauty routine to the next levelFebruary 7, 2022 | seekingalpha.comSecond Sight Medical Products to acquire Nano Precision Medical in all-stock dealFebruary 7, 2022 | finance.yahoo.comSecond Sight Medical Products and Nano Precision Medical Announce Merger Agreement to Create Leading Therapeutic Implant CompanyFebruary 3, 2022 | cnet.comGet two glasses for the price of one with DIFF eyewear's BOGO saleNovember 11, 2021 | nz.finance.yahoo.comeSight Certified as a Great Place to Work® for Second Year in a RowSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Electromedical equipment Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EYES CUSIPN/A CIK1266806 Webwww.secondsight.com Phone(818) 833-5000Fax818-833-5067Employees15Year FoundedN/ACompany Calendar Last Earnings6/29/2020Today6/29/2022Fiscal Year End12/31/2022Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8.92 million Net MarginsN/A Pretax MarginN/A Return on Equity-12.00% Return on Assets-11.48% Debt Debt-to-Equity RatioN/A Current Ratio25.25 Quick Ratio25.25 Sales & Book Value Annual Sales$3.38 million Price / Sales24.25 Cash FlowN/A Price / Cash FlowN/A Book Value$1.73 per share Price / Book1.20Miscellaneous Outstanding Shares39,409,000Free Float20,808,000Market Cap$81.97 million OptionableOptionable Beta2.81 Second Sight Medical Products Frequently Asked Questions How has Second Sight Medical Products' stock performed in 2022? Second Sight Medical Products' stock was trading at $1.63 at the start of the year. Since then, EYES shares have increased by 27.6% and is now trading at $2.08. View the best growth stocks for 2022 here. How were Second Sight Medical Products' earnings last quarter? Second Sight Medical Products, Inc. (NASDAQ:EYES) issued its quarterly earnings results on Monday, June, 29th. The medical device company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by $0.16. View Second Sight Medical Products' earnings history. Who are Second Sight Medical Products' key executives? Second Sight Medical Products' management team includes the following people: Mr. Scott Dunbar, Acting Chief Exec. Officer (Age 64, Pay $301.39k)Mr. Edward Jonathon Sedo, Acting Chief Accounting Officer, Principal Financial Officer & Controller (Age 66, Pay $199.18k)Mr. Edward David Randolph, Chief Operating Officer (Age 64, Pay $366.44k)Dr. Jessy Dana Dorn Ph.D., VP of Clinical & Scientific Affairs (Age 46, Pay $282.7k)Gunnar Bjorg, FounderMs. Lisa M. Wilson, Founder & Pres of In-Site Communications and Investor Relations for Second Sight (Age 57) What is Will McGuire's approval rating as Second Sight Medical Products' CEO? 5 employees have rated Second Sight Medical Products CEO Will McGuire on Glassdoor.com. Will McGuire has an approval rating of 57% among Second Sight Medical Products' employees. This puts Will McGuire in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. Who are some of Second Sight Medical Products' key competitors? Some companies that are related to Second Sight Medical Products include Zynex (ZYXI), Edap Tms (EDAP), Semler Scientific (SMLR), Hyperfine (HYPR), Stereotaxis (STXS), FONAR (FONR), Movano (MOVE), Electromed (ELMD), Electromed (ELMD), IRIDEX (IRIX), Fc Global Realty (FCRE), electroCore (ECOR), Precision Optics (PEYE), Yubo International Biotech (YBGJ) and BioSig Technologies (BSGM). View all of EYES's competitors. What other stocks do shareholders of Second Sight Medical Products own? Based on aggregate information from My MarketBeat watchlists, some companies that other Second Sight Medical Products investors own include Zynerba Pharmaceuticals (ZYNE), Adaptimmune Therapeutics (ADAP), Cara Therapeutics (CARA), VBI Vaccines (VBIV), Shopify (SHOP), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), (CGC), Ekso Bionics (EKSO) and OPKO Health (OPK). When did Second Sight Medical Products IPO? (EYES) raised $32 million in an IPO on Wednesday, November 19th 2014. The company issued 3,500,000 shares at a price of $9.00 per share. MDB Capital Group, LLC served as the underwriter for the IPO. What is Second Sight Medical Products' stock symbol? Second Sight Medical Products trades on the NASDAQ under the ticker symbol "EYES." Who are Second Sight Medical Products' major shareholders? Second Sight Medical Products' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (3.10%), Renaissance Technologies LLC (0.44%), Simplex Trading LLC (0.00%), Cutler Group LP (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Company insiders that own Second Sight Medical Products stock include Gregg Williams and Jonathan Will Mcguire. View institutional ownership trends for Second Sight Medical Products. Which institutional investors are selling Second Sight Medical Products stock? EYES stock was sold by a variety of institutional investors in the last quarter, including Simplex Trading LLC, and Cutler Group LP. View insider buying and selling activity for Second Sight Medical Products or view top insider-selling stocks. Which institutional investors are buying Second Sight Medical Products stock? EYES stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, and Vanguard Group Inc.. View insider buying and selling activity for Second Sight Medical Products or or view top insider-buying stocks. How do I buy shares of Second Sight Medical Products? Shares of EYES can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Second Sight Medical Products' stock price today? One share of EYES stock can currently be purchased for approximately $2.08. How much money does Second Sight Medical Products make? Second Sight Medical Products (NASDAQ:EYES) has a market capitalization of $81.97 million and generates $3.38 million in revenue each year. How many employees does Second Sight Medical Products have? Second Sight Medical Products employs 15 workers across the globe. How can I contact Second Sight Medical Products? Second Sight Medical Products' mailing address is 12744 SAN FERNANDO ROAD SUITE 400, SYLMAR CA, 91342. The official website for Second Sight Medical Products is www.secondsight.com. The medical device company can be reached via phone at (818) 833-5000, via email at [email protected], or via fax at 818-833-5067. This page (NASDAQ:EYES) was last updated on 6/29/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
